Evaxion Reports Strong 2025 Financial Turnaround, Secures Major $592M MSD Licensing Deal

summarizeSummary

Evaxion A/S reported a significant financial improvement in 2025, moving from a negative to positive equity position and substantially increasing cash, driven by a landmark licensing agreement with MSD for its EVX-B3 vaccine candidate worth up to $592 million in milestones and royalties.

check_boxKey Events

• Major Licensing Deal Secured

  MSD licensed Evaxion's EVX-B3 vaccine candidate, offering up to $592 million in potential development, regulatory, and sales milestone payments, plus royalties on net sales. MSD will bear all future development costs.

• Significant Financial Improvement

  The company's total equity turned positive to $17.0 million in 2025 from a $1.7 million deficit in 2024, and cash and cash equivalents increased to $23.2 million from $6.0 million.

• Nasdaq Compliance Restored

  Evaxion regained compliance with Nasdaq listing requirements in February 2025, resolving a delisting notice received in November 2024.

• Positive Clinical Data Reported

  Encouraging 2-year Phase 2 clinical efficacy data for its EVX-01 melanoma vaccine candidate was presented, showing a 75% Objective Response Rate and 92% of patients still responding at 24 months.

auto_awesomeAnalysis

Evaxion's 2025 annual report highlights a critical turnaround, with the company's equity shifting from a $1.7 million deficit in 2024 to a positive $17.0 million, and cash reserves increasing nearly fourfold to $23.2 million. This financial strengthening is largely attributed to a transformative licensing deal with MSD for the EVX-B3 vaccine candidate, which includes up to $592 million in potential milestone payments and royalties, with MSD assuming all future development costs. This deal provides substantial external validation for Evaxion's AI-Immunology™ platform and significantly de-risks its pipeline. The company also successfully resolved a Nasdaq delisting notice from November 2024 by regaining compliance in February 2025. While the year included a 1-for-5 ADS ratio change (reverse split effect) and a share capital reduction to cover losses, these actions, coupled with public offerings and ATM sales, contributed to the improved liquidity and capital structure, positioning Evaxion for continued development of its AI-driven vaccine candidates.